Compare DIOD & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIOD | LQDA |
|---|---|---|
| Founded | 1959 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 1995 | 2020 |
| Metric | DIOD | LQDA |
|---|---|---|
| Price | $103.93 | $37.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $92.67 | $41.00 |
| AVG Volume (30 Days) | 488.9K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.53 | ★ 51.81 |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $18.08 | $278.87 |
| Revenue Next Year | $14.46 | $57.13 |
| P/E Ratio | $70.15 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $36.75 | $11.85 |
| 52 Week High | $101.92 | $46.67 |
| Indicator | DIOD | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 84.61 | 47.96 |
| Support Level | $49.99 | $31.75 |
| Resistance Level | N/A | $39.19 |
| Average True Range (ATR) | 3.64 | 1.98 |
| MACD | 1.69 | -0.28 |
| Stochastic Oscillator | 90.02 | 21.13 |
Diodes Inc is a manufacturer and supplier of high-quality application-specific products within the broad discrete, logic, analog, and mixed-signal semiconductor markets. It serves the customer electronics, computing, communications, industrial, and automotive markets. The Company's products include diodes; rectifiers; transistors; MOSFETs; GPP bridges; GPP rectifiers; protection devices; function-specific arrays; single gate logic; amplifiers and comparators; Hall-effect and temperature sensors; and power management devices, including LED drivers, AC-DC converters and controllers, DC-DC switching and linear voltage regulators, voltage references along with special-function devices, such as USB power switches, load switches, voltage supervisors, and motor controllers.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.